The DDW Turning Science into Business Summit, ‘Cancer research opportunities and advances’ will feature an expert panel discussion on new drug discovery and development concepts and tools in cancer research.
The free two-hour Summit, hosted by DDW, will take place online on 16 November at 7AM PDT / 10AM EDT / 3PM GMT / 4PM CET.
Experts and thought leaders in cancer research, precision medicine and immunotherapy will describe the latest research and the role of technology to help discover targets, develop cancer therapeutics and vaccines, and get to market faster.
The main presentations will be followed by a panel discussion on how these new approaches – e.g., engineered proteins, antibodies, micro RNA, nanocarriers, antibody drug conjugates – can help address unmet need in oncology.
Our panellists bring extensive cancer drug discovery expertise and knowledge from a range of different perspectives and backgrounds. So who are they?
Joseph R Peterson, PhD, CTO & Co-founder, SimBioSys: Precision cancer expert SimBioSys integrates patient-specific data and biological simulations to predict response to cancer therapy. CTO and co-founder Joseph R Peterson has an acute interest in integrating multi-scale data via AI and spatial biophysics to create 4D digital twins that serve as virtual trials in both discovery and clinical settings.
Dr Xueming Qian, PhD, CEO of Transcenta: Transcenta was recently granted clearance by the FDA to proceed with a global Phase III trial of its candidate Osemitamab as first-line treatment for gastric/gastroesophageal cancer. Dr Qian has nearly 30 years of industrial antibody discovery and development experience and is the leading inventor of multiple antibody patents.
Dr Michael Seiler, Vice President of Commercial Products, Taconic Biosciences: A trained immunologist, Dr Seiler earned his PhD in cell and molecular biology at the Baylor College of Medicine and worked in the lab of renowned immunologist Dr Albert Bendelac at the University of Chicago. He joined Taconic Biosciences in 2014 has been the Vice President of Commercial Products since 2017.
Spiro Rombotis, CEO, Cyclacel: Cyclacel is a pioneer in the field of cell cycle biology to treat cancer. The company’s CEO, Spire Rombotis, has over 36 years’ experience in the industry, and has participated in the commercial launch of several drugs, including Abelcet, Evacet/Myocet, ProHance, Remicade and Reopro.
